Kyowa Kirin said on August 1 that it is offering a voluntary redundancy program targeting certain research-related divisions as part of its efforts to sharpen its focus on priority disease areas and modalities and pivot away from small-molecule drug discoveries.…
To read the full story
Related Article
- Kyowa Kirin Announces Another Buyout Package; Job Cut Target Not Set
May 8, 2025
- Kyowa Kirin Sees Need for Shift of Japan Business: CEO
February 10, 2025
- Kyowa Kirin Not Ruling Out Small Molecule Drug Research: CMO
August 5, 2024
BUSINESS
- Merck Biopharma Starts Japan PIII Trial of LH/FSH Combo
July 17, 2026
- Eisai’s Dayvigo Accepted for EMA Review
July 17, 2026
- AbbVie Files Maviret for Acute Hepatitis C
July 17, 2026
- FRONTEO, Santen Advance AI Drug Discovery Project to Second Phase
July 17, 2026
- Ferring’s Adstiladrin, Boehringer’s Jascayd Hit Market; Haizexin Due July 28
July 16, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





